Part A: Market Impact
Celltrion Inc. (068270.KS, KOSPI) presented long-term Phase 3 clinical data for its flagship subcutaneous biosimilar Remsima SC at AOCC&IMKASID 2026 in Seoul on Wednesday, underscoring an accelerating commercial trajectory that has pushed the drug to a 31% market share in Europe's five largest markets (EU5) as of Q4 2025.
The data, earlier previewed at the American Gastroenterological Association's Digestive Disease Week (DDW), showed that patients with Crohn's disease who switched from the intravenous formulation to the subcutaneous injection maintained endoscopic remission steadily over a 44-week period with no new safety signals identified.
In the United States, where Remsima SC is marketed under the brand name Zimpetra, prescriptions in Q1 2026 surged more than threefold versus the same quarter a year earlier, signalling rapid formulary penetration despite the competitive biosimilar infliximab market.
The double validation — durable Phase 3 data plus commercial momentum — reinforces Celltrion's positioning as one of the few biosimilar developers with a subcutaneous administration advantage over the original intravenous Remicade franchise.
Part B: What It Means for Investors
Clinical significance: The 44-week endoscopic remission maintenance in a switch population (IV to SC, 60 Japanese patients) is the most demanding proof-of-concept for SC biosimilars. Gastroenterologists require endoscopic evidence — not just symptom scores — to trust long-term label switches. A clean readout at this threshold lowers prescriber hesitation and accelerates real-world uptake.
EU5 share context: A 31% market share in the combined UK, Germany, France, Italy and Spain infliximab market positions Remsima SC as the category leader among SC formulations. The originator Remicade (IV) and its biosimilar successors compete on price, but SC convenience has been the decisive differentiator.
US traction: The Zimpetra prescription triple — achieved in the first full year of broad commercial launch — tracks ahead of the typical biosimilar ramp. Pharmacy benefit managers (PBMs) and integrated delivery networks (IDNs) have historically taken 18–24 months to widen formulary access; a 3x surge in a single quarter suggests accelerated payer acceptance.
Hedge: Q1 2026 US growth figures are prescription counts, not revenue, and Celltrion has not disclosed average selling prices or rebate structures for Zimpetra. Investors should verify sales revenue when full Q2 financials are released. European pricing pressure from competing biosimilars (Pfizer Inflectra, Fresenius Kabi Flixabi) remains an ongoing headwind.
Key numbers: - EU5 infliximab SC market share: 31% (Q4 2025) - US Zimpetra prescriptions: >3x YoY (Q1 2026) - Phase 3 study: 60 Crohn disease patients, IV-to-SC switch, 44-week maintenance endpoint - Conference: AOCC&IMKASID 2026, Seoul, through June 27
Sources: ETNews, Yonhap News Agency, AOCC&IMKASID 2026 conference proceedings.
